Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Emerg Microbes Infect
; 10(1): 1241-1243, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1258725
ABSTRACT
In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Antibodies, Viral
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Emerg Microbes Infect
Year:
2021
Document Type:
Article
Affiliation country:
22221751.2021.1940305
Similar
MEDLINE
...
LILACS
LIS